Should You Buy CytomX Therapeutics Inc (CTMX) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
Not a good buy right now for a beginner long-term investor who is impatient. CTMX is technically extended (RSI elevated and price near resistance) with a high-volatility options market and recent insider selling. While Wall Street is bullish ahead of upcoming clinical updates, the risk/reward at the current ~$5.89 level looks better after a pullback or a clearer breakout above resistance with follow-through.
Technical Analysis
Price/Trend: Bullish trend structure with moving averages stacked positively (SMA_5 > SMA_20 > SMA_200), and MACD histogram positive and expanding (momentum still up).
Overbought/Entry Risk: RSI_6 ~76 suggests the stock is stretched short-term; that often raises the odds of a near-term dip/consolidation even in an uptrend.
Key Levels: Pivot ~5.185. Immediate resistance R1 ~5.97 (price ~5.885 is close), next resistance R2 ~6.455. Supports: S1 ~4.40 then S2 ~3.915.
Pattern/Short-horizon odds: The provided pattern stats imply a mild bearish bias near-term (80% chance of about -2% next day, -2.6% next week).
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Analyst Ratings and Price Target Trends
Recent trend: Strongly improving/bullish. Since Nov 2025 through Jan 2026, multiple firms raised price targets and reiterated/initiated Buy/Overweight: Barclays raised to $8 (Overweight), Piper Sandler raised to $10 (Overweight), Guggenheim initiated Buy at $10, and H.C. Wainwright raised to $10 (Buy).
Wall Street pros: (1) Encouraging early clinical efficacy signals (e.g., ORR/DCR/PFS commentary) and (2) meaningful upside optionality if mCRC data continue to validate the program.
Wall Street cons: (1) High binary clinical risk and (2) weak current financial profile (declining revenue and ongoing losses), making valuation highly dependent on trial outcomes.
Politicians/Congress: No recent congress trading data available in the last 90 days.
Wall Street analysts forecast CTMX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTMX is 7.1 USD with a low forecast of 6 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast CTMX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTMX is 7.1 USD with a low forecast of 6 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 5.740
Current: 5.740
